Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Panel Nudges Eisai Towards Phase IV Compliance For Halaven

Executive Summary

Eisai’s request to forego Phase IV studies for its anticancer, Halaven, has been turned down by an Indian expert panel, which has reminded the Japanese company of the conditional marketing authorization previously granted for the product. Eisai, for its part, now says it will follow the “necessary requirements” set out by the Indian regulator.

You may also be interested in...



Why Pharma Doesn't Always Keep Phase IV Promises In India

Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.

Keytruda’s Catch-22 Situation In India Amid Compliance Questions

Merck & Co’s immuno-oncology therapy Keytruda appears be facing a rather paradoxical situation in India, after an expert panel noted that the US multinational had failed to comply with Phase IV study requirements pertaining to the product in the country.

Eisai Fortifies Play With India-Specific Priced Fycompa

Eisai expects products like Fycompa and Lenvima, backed by innovative price planks pivoted around improving patient access, to intensify growth in India. Fycompa now debuts at a sub-$1 per day pricing in India.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel